PSTV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Plus Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.43.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 48.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 62.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 65.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Plus Therapeutics was 81.70% per year. The lowest was -89.20% per year. And the median was 28.60% per year.
For the Biotechnology subindustry, Plus Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Plus Therapeutics (NAS:PSTV) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of Plus Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Marc H Hedrick | officer: President | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Robert P Lenk | director | LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
Howard Clowes | director | 217 DWIGHT ROAD, BURLINGAME CA 94010 |
Greg Petersen | director | 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
Sims Andrew John Hugh Macintyre | officer: Chief Financial Officer | 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
Norman D. Lafrance | officer: CHIEF MEDICAL OFFICER | MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
Ag Postfinance | 10 percent owner | MINGERSTRASSE 20, BERN V8 3030 |
Bank Sa Swissquote | 10 percent owner | CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Ron Martell | director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Mark Marino | officer: Chief Medical Officer | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
John David Harris | officer: VP and GM of Cell Therapy | 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
David Rickey | director |
From GuruFocus
By PRNewswire • 11-14-2023
By Marketwired • 10-10-2023
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 08-30-2023
By sperokesalga sperokesalga • 05-30-2023
By sperokesalga sperokesalga • 05-25-2023
By Marketwired • 07-13-2023
By Marketwired • 08-08-2023
By Marketwired • 10-09-2023
By GuruFocus Research • 09-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.